Cerenome Reports First Commercial Diagnostic Revenue and Q3 2026 Financial Results

Cerenome (CNSY) has officially transitioned its CNSide platform from a development phase to commercial operations, reporting $0.7 million in net diagnostic revenue for the third quarter of 2026. The company saw gross billings reach $1.55 million from 222 submitted claims and reported an expansion of its provider network to 45 providers across 26 institutions. While operating losses widened to $7.5 million due to increased commercial team spending, management provided optimistic long-term guidance. The company expects annualized gross billings to reach $10 million–$12.5 million by the end of 2026, with a projected jump to $20 million–$25 million in 2027. Key milestones include expected Medicare reimbursement in the first half of 2027 and the successful closure of Phase II glioblastoma trial enrollment.

By Motley Fool Transcribing · Motley Fool ·

Cerenome Reports First Commercial Diagnostic Revenue and Q3 2026 Financial Results

Topics: billing guidance commercial recognition market penetration revenue growth

Read the full article at Motley Fool

Part of the story Cerenome Reports First Commercial Diagnostic Revenue and Q3 2026 Financial Results (2 articles)

More World news